How a protein called NHERF1 controls mast cell reactions in allergic diseases
NHERF1 regulates MRGPRX2/MrgprB2 responses in mast cells
This project aims to understand how a specific protein affects mast cells, which are key players in allergic reactions and conditions like asthma and rosacea.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10886790 on NIH RePORTER |
What this research studies
Mast cells are immune cells in our tissues that are well-known for causing allergic reactions. Recently, scientists discovered a receptor called MRGPRX2 on these mast cells that can trigger pseudoallergic reactions to certain medications and contribute to chronic inflammation in conditions like asthma, rosacea, and hives. While we know MRGPRX2 is involved, we don't fully understand how it works at a molecular level. This research explores how another protein, NHERF1, helps regulate these MRGPRX2 responses in mast cells. By studying this interaction, we hope to uncover the fundamental ways mast cells contribute to allergic diseases.
Who could benefit from this research
Good fit: This foundational research is relevant for patients living with allergic diseases, asthma, rosacea, or chronic hives, as it seeks to understand the underlying biological mechanisms of their conditions.
Not a fit: Patients will not receive direct clinical benefit from participating in this basic science project, as it focuses on understanding disease mechanisms rather than testing new treatments.
Why it matters
Potential benefit: If successful, this work could lead to new ways to target and control allergic reactions and chronic inflammatory conditions by understanding the role of NHERF1 in mast cells.
How similar studies have performed: Preliminary data from the researchers suggest NHERF1 plays a role in mast cell responses, and this project builds upon those initial observations to explore a novel molecular mechanism.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Laumet, Geoffroy O — Michigan State University
- Study coordinator: Laumet, Geoffroy O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.